The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study.
 
Adrian G. Sacher
No Relationships to Disclose
 
Lynette M. Sholl
No Relationships to Disclose
 
Stacy L. Mach
No Relationships to Disclose
 
Bruce E. Johnson
Stock and Other Ownership Interests - KEW
Honoraria - Chugai Pharma; Merck
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Dana-Farber Cancer Institute; GE Healthcare; KEW; Merck; Novartis; Otsuka; Puma Biotechnology; Synta; Teva; Transgene
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
Expert Testimony - Genentech
 
Peter S. Hammerman
No Relationships to Disclose
 
Pasi A. Janne
Stock and Other Ownership Interests - GATEKEEPER Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis Oncology; Genentech; Merrimack; Pfizer; Roche Pharma AG; Sanofi
Other Relationship - LabCorp
 
Geoffrey R. Oxnard
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - Patent pending